Alternatives to Italy – Hospital beds – Letti medici

Italy – Various medicinal products – Radiofarmaci

Italy – Miscellaneous medical devices and products – PROCEDURA APERTA PER LA FORNITURA IN ACCORDO QUADRO DM PER L'ATTIVITA' DI CHIRURGIA VASCOLARE E DI RADIOLOGIA INTERVENTISTICA PER LE ESIGENZE DELLE AZIENDE SANITARIE E OSPEDALIERE AVEC. IMPORTO DELLA

Italy – Social work services without accommodation – PROCEDURA APERTA

Italy – Social services – affidamento della gestione del servizio di microstruttura del Comune di Merano - 3 lotti

Italy – Social work services with accommodation – AFFIDAMENTO DEI SERVIZI DI ACCOGLIENZA, TUTELA ED INTEGRAZIONE NELL’AMBITO DELLA RETE SAI - CATEGORIA ORDINARI - CATEGORIA MSNA - CATEGORIA DISABILI.

Italy – Miscellaneous medical devices and products – SUPPORTI CHIRURGICI PER RICOSTRUZIONE MAMMARIA

Italy – Social services – Centro Fregosi

Italy – Social work services with accommodation – GESTIONE DI AZIONI E SERVIZI DI ACCOGLIENZA INTEGRATA PER I RICHIEDENTI PROTEZIONE INTERNAZIONALE, ASILO E I RIFUGIATI, RELATIVO AL PROGETTO SAI COMUNE DI CERZETO PER IL TRIENNIO 2026/2028

Italy – Welfare services for the handicapped – SUA PROVINCIA DI PIACENZA P/C DEL COMUNE DI BORGONOVO VAL TIDONE: PROCEDURA APERTA PER L’AFFIDAMENTO DEL SERVIZIO DI ASSISTENZA SCOLASTICA ED EXTRASCOLASTICA A FAVORE DI ALUNNI DISABILI E DEL SERVIZIO

Italy – Endoscopy, endosurgery devices – GARA EUROPEA A PROCEDURA APERTA PER L’AFFIDAMENTO DI N. 1 COLONNA ENDOSCOPICA

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…